Table 1.
Summary of the published articles of HT for Helicobacter pylori eradication
| First author, year | Region | Centers (n) | Cases (n) | Study type | Control groups | Duration of HT (d) | Regimens of HT | Cure rate of ITT (%) | Cure rate of PP (%) | Compliance (%) | Overall rate of adverse effects (%) | Discontinued medication due to adverse effects (%) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hsu, 2011[6,16] | Taiwan, China | 3 | 117 | RCT | 14d ST | 7 + 7 | E 40 mg | A 1 g | C 0.5 g | M 0.5 g | 97.4 | 99.1 | 94.9 | 14.5 | 4.3 |
| Sardarian, 2013[17] | Iran | 1 | 210 | RCT | 10d ST | 7 + 7 | P 40 mg | A 1 g | C 0.5 g | T 0.5 g | 89.5 | 92.9 | 96.7 | 28.1 | 1.4 |
| Molina-Infante, 2013[10] | Spain/Italy | 4 | 171 | RCT | 14d CT | 7 + 7 | O 40 mg | A 1 g | C 0.5 g | M/T 0.5 g | 90.0 | 92.0 | 98.8 | 47.0 | 2.4 |
| Zullo, 2013[18] | Italy | 3 | 90 | RCT | 10d ST 5d CT | 7 + 7 | O 20 mg | A 1g | C 0.5 g | T 0.5 g | 80.0 | 85.7 | 93.3 | 24.4 | 6.7 |
| Oh, 2014[11] | Korea | 1 | 90 | RCT | 14d ST | 7 + 7 | R 20 mg | A 1 g | C 0.5 g | M 0.5 g | 81.1 | 85.9 | 97.7 | 33.7 | 3.5 |
| De Francesco, 2014[19] | Italy | 1 | 110 | RCT | 10d ST 5d CT 14d CT | 7 + 7 | O 20 mg | A 1 g | C 0.5 g | T 0.5 g | 82.7 | 95.8 | NR | 22.7 | 6.4 |
| Wu, 2014[12] | Taiwan, China | 3 | 77 | RCT | 12d HT 14d HT | 3 + 7 | E 40 mg | A 1 g | C 0.5 g | M 0.5 g | 81.8 | 95.0 | 94.0 | 14.7 | NR |
| Wu, 2014[12] | Taiwan, China | 3 | 73 | RCT | 10d HT 14d HT | 5 + 7 | E 40 mg | A 1 g | C 0.5 g | M 0.5 g | 86.3 | 95.1 | 97.0 | 17.1 | NR |
| Wu, 2014[12] | Taiwan, China | 3 | 70 | RCT | 10d HT 12d HT | 7 + 7 | E 40 mg | A 1 g | C 0.5 g | M 0.5 g | 85.7 | 93.4 | 95.6 | 17.6 | NR |
| Cuadrado-Lavín, 2015[13] | Spain | 3 | 120 | RCT | 10d TT 10d CT | 5 + 5 | O 20 mg | A 1 g | C 0.5 g | M 0.5 g* | 90.8 | 93.9 | 98.3 | 67.5 | 1.7 |
| Metanat, 2015[15] | Iran | 1 | 134 | RCT | 14d HT | 5 + 5 | P 40 mg | A 1 g | C 0.5 g | T 0.5 g | 77.6 | 83.9 | 96.3 | 38.1 | 3.0 |
| Metanat, 2015[15] | Iran | 1 | 136 | RCT | 10d HT | 7 + 7 | P 40 mg | A 1 g | C 0.5 g | T 0.5 g | 86.0 | 92.9 | 95.6 | 38.2 | 3.7 |
| Heo, 2015[14] | Korea | 6 | 241 | RCT | 10d CT | 5 + 5 | E 20 mg | A 1 g | C 0.5 g | M 0.5 g | 78.8 | 89.6 | 95.0 | NR | 0 |
| Chen, 2015[8] | Taiwan, China | 1 | 88 | RCT | 10d ST | 7 + 7 | R 20 mg | A 1 g | C 0.5 g | M 0.5 g | 92.0 | 96.4 | 97.7 | 59.1 | 2.3 |
| Hwang, 2015[9] | Korea | 1 | 144 | RCT | 14d MBST | 7 + 7 | R 20 mg | A 1 g | C 0.5 g | M 0.5 g | 79.2 | 82.6 | 100 | 19.6 | 0 |
| Pooled-data analysis | 1871 | 85.1 (1592/1870) | 91.2 (1554/1704) | 96.6 (1648/1706) | 32.9 (529/1610) | 2.5 (41/1612) | |||||||||
*Three times a day, and the others twice a day. A: Amoxicillin; C: Clarithromycin; CT: Concomitant therapy; E: Esomeprazole; HT: Hybrid therapy; M: Metronidazole; MBST: Moxifloxacin-containing sequential therapy; NR: Not reported; O: Omeprazole; P: Pantoprazole; R: Rabeprazole; RCT: Randomized controlled trial; ST: Sequential therapy; T: Tinidazole; TT: Triple therapy; PP: Per-protocol; ITT: Intention-to-treat; d: Days.